Evidence map›Paper›PMID 38204269›Full record

ArticleRecent patents on anti-cancer drug discovery2025

TENT5A Increases Glioma Malignancy and Promotes its Progression.

Jiali Hu, Lei Zeng, Ronghuan Hu, Dan Gong, Mengmeng Liu, Jianwu Ding

Abstract read
PubMed Publisher
In one paragraph

Article in Recent patents on anti-cancer drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiali HuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Lei ZengDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Ronghuan HuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Dan GongDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Mengmeng LiuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Jianwu DingDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Funding

National Natural Science Foundation of China 81960544
6 · The paper itself

Abstract

backgroundRecent studies reported that terminal nucleotidyltransferase 5A (TENT5A) is highly expressed in glioblastoma and associated with poor prognosis. In this work, we aim to specify the expression level of TENT5A in different grades of glioma and explore its role in glioma progression.

methodsGEPIA online tools were used to perform the bioinformatic analysis. qRT-PCR, Western blot, and Immunohistochemistry were performed in glioma cells or tissues. Furthermore, CCK8, colony formation, transwell, flow cytometry and scratch assays were performed.

resultsTENT5A was highly expressed in glioma and its level was associated with the pathological grade of glioma. Knockdown of TENT5A suppressed cell proliferation, colony formation ability, cell invasion and migration. Overexpression of TENT5A was lethal to the glioma cells.

conclusionOur data showed that the expression of TENT5A is associated with the pathological grade of glioma. Knockdown of TENT5A decreased the ability of proliferation, invasion and migration of glioma cells. High levels of TENT5A in glioma cells are lethal. Therefore, TENT5A could be a new target for glioma treatment.

Indexed as

Brain NeoplasmsGliomaCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMaleNeoplasm GradingNeoplasm InvasivenessGliomainvasionlethal.migrationproliferationTENT5A

Identifiers

PMID38204269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.